Biorestorative Therapies (BRTX) Stock Price, News & Analysis

Company Overview

Biorestorative Therapies Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.

Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy. Biorestorative Therapies’ candidate has completed early-stage clinical evaluation and is advancing through planned trials to assess safety and efficacy in reducing the duration and severity of oral mucositis. Preclinical studies have also been conducted to explore additional indications, including inflammatory and degenerative conditions.

Headquartered in Malvern, Pennsylvania, Biorestorative Therapies manages its research, manufacturing and clinical development activities in the United States. The company works with clinical research organizations and academic centers to support its ongoing trials and maintains a leadership team with experience spanning cell therapy, clinical development and regulatory affairs. Biorestorative Therapies continues to pursue partnerships to expand its pipeline and accelerate the path to potential regulatory approval.

Key Stats

• Today's Range: $1.59 to $1.72
• 50-Day Range: $1.41 to $1.84
• 52-Week Range: $1.19 to $2.55
• Volume: 56,535 shs
• Average Volume: 78,818 shs
• Market Capitalization: $12.93 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Biorestorative Therapies Stock Analysis - MarketRank™

Biorestorative Therapies scored higher than 44% of companies evaluated by MarketBeat, and ranked 660th out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Biorestorative Therapies.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Biorestorative Therapies are expected to grow in the coming year, from ($1.43) to ($0.86) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Biorestorative Therapies is -1.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Biorestorative Therapies is -1.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Biorestorative Therapies has a P/B Ratio of 1.32. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.85% of the float of Biorestorative Therapies has been sold short.

Short Interest Ratio / Days to Cover

Biorestorative Therapies has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Biorestorative Therapies has recently decreased by 24.51%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Biorestorative Therapies does not currently pay a dividend.

Dividend Growth

Biorestorative Therapies does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.85% of the float of Biorestorative Therapies has been sold short.

Short Interest Ratio / Days to Cover

Biorestorative Therapies has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Biorestorative Therapies has recently decreased by 24.51%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.47

News Sentiment

Biorestorative Therapies has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Biorestorative Therapies this week, compared to 1 article on an average week.

Search Interest

7 people have searched for BRTX on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.

MarketBeat Follows

2 people have added Biorestorative Therapies to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Biorestorative Therapies insiders have not sold or bought any company stock.

Percentage Held by Insiders

30.80% of the stock of Biorestorative Therapies is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

69.38% of the stock of Biorestorative Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

BRTX Stock Analysis - Frequently Asked Questions

How have BRTX shares performed this year?

Biorestorative Therapies' stock was trading at $1.43 at the beginning of 2025. Since then, BRTX shares have increased by 13.3% and is now trading at $1.62.

How were Biorestorative Therapies' earnings last quarter?

Biorestorative Therapies, Inc. (NASDAQ:BRTX) posted its quarterly earnings results on Tuesday, August, 12th. The company reported ($0.30) EPS for the quarter, topping analysts' consensus estimates of ($0.41) by $0.11. The company earned $0.30 million during the quarter, compared to analyst estimates of $0.34 million. Biorestorative Therapies had a negative net margin of 1,772.40% and a negative trailing twelve-month return on equity of 137.00%.
Read the conference call transcript.

Is Biorestorative Therapies doing a stock buyback?

Biorestorative Therapies' Board of Directors initiated a stock repurchase plan on Tuesday, June 17th 2025, which authorizes the company to repurchase $2,000,000 in shares, according to EventVestor. This means that the company could purchase up to 15.9% of its stock through open market purchases. Stock buyback plans are generally an indication that the company's board of directors believes its shares are undervalued.

How do I buy shares of Biorestorative Therapies?

Shares of BRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Biorestorative Therapies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Biorestorative Therapies investors own include NVIDIA (NVDA), Micron Technology (MU), PayPal (PYPL), Advanced Micro Devices (AMD), Avino Silver & Gold Mines (ASM), Broadcom (AVGO) and AstraZeneca (AZN).

Company Calendar

• Last Earnings: 8/12/2025
• Today: 10/11/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:BRTX
• CIK: 1505497
• Web: www.biorestorative.com
• Phone: 631-760-8100
• Fax: N/A
• Employees: 7
• Year Founded: 1997

Profitability

• EPS (Trailing Twelve Months): ($1.27)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.98 million
• Net Margins: -1,772.40%
• Pretax Margin: -1,772.40%
• Return on Equity: -137.00%
• Return on Assets: -88.31%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.07
• Quick Ratio: 2.07

Sales & Book Value

• Annual Sales: $400 thousand
• Price / Sales: 32.32
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.23 per share
• Price / Book: 1.32

Miscellaneous

• Outstanding Shares: 7,980,000
• Free Float: 5,521,000
• Market Cap: $12.93 million
• Optionable: Not Optionable
• Beta: -0.69